All News

This week, the Center on Health Equity and Access covered the release of the best US hospitals for equitable access, news from the CMS Health Equity conference, biomarker testing legislation, and insights on improving access for queer communities and the disparities in dermatology.

The data come from the observational Cost of Hemophilia in Europe: A Socioeconomic Survey II (CHESS II) study of 288 Spanish patients with hemophilia A and B, which showed certain differences between disease subtypes but overall similar trends in disease impact.

Tumor necrosis factor (TNF) inhibitor use was associated with a lower risk of cardiovascular outcomes in patients with radiographic axial spondyloarthritis in a recent study.

During the CMS Health Equity conference, the “Implementing Health Equity Through Value-Based Care for People in Medicare” session featured a series of expert speakers who shared insights on pioneering strategies designed to advance health equity.

Respiratory syncytial virus (RSV) hospitalization–related features may help inform prevention approaches among children with the infection, according to one study.

Patients with moderate to severe psoriasis may benefit from weekend cyclosporine treatment (WCT) as a maintenance therapy, according to one study.

Initiatives that encourage or mandate collecting LGBTQ+ data could provide a plethora of benefits for clinicians and health care providers, from identifying disparities to creating stronger, more trusting relationships between LGBTQ+ patients and the health care system.

Having a higher magnesium depletion score (MDS) independently predicts increased all-cause and cardiovascular mortality risks in US patients with hypertension (HTN), emphasizing the importance of early HTN prevention and magnesium deficiency management.

A small cohort demonstrated the potential benefits aerobic exercise regimens hold for managing fatigue symptoms in multiple sclerosis (MS), but more studies are needed.

Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, discusses an ongoing trial and novel development in plasminogen deficiency type 1.

Going forward, the federal government must pay potentially hundreds of millions more to underfunded Native American tribes with health care programs; the FDA reversed its ban on Juul e-cigarettes yesterday as it reviews new court decisions and updated information; hospitals nationwide are experiencing workforce shortages as doctors and nurses increasingly leave the field.

An abstract presented at the 2024 American Society of Clinical Oncology annual meeting showed that patients treated with zanubrutinib or acalabrutinib had more favorable safety and efficacy outcomes.

A small retrospective study found that combining obinutuzumab with radiation therapy may offer a viable and well-tolerated treatment option for patients with refractory diffuse large B-cell lymphoma (DLBCL).

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The latest approval of lisocabtagene maraleucel (liso-cel) in mantle cell lymphoma provides another treatment option and continues the tremendous advances in treatment for patients, said Christopher Flowers, MD, of MD Anderson Cancer Center.

Synthesizing 11 qualitative studies, authors present a nuanced picture of how patients with type 1 diabetes (T1D), and the health care professionals (HCPs) who treat them, feel about using social media platforms as a self-management tool—and where improvements can be made.

The authors said their analysis should help clinicians better monitor patients for potential adverse events.

Researchers say their findings will help inform treatment protocols for this patient population, as questions remain about optimal duration of these treatments following first-line treatment with pyridostigmine.

US tuberculosis (TB) programs have helped to identify those with TB and latent TB infection and ensure they completed treatment; FDA advisers instructed that the COVID-19 vaccine Americans will receive in the fall should target the JN.1 strain; lawmakers are divided over the CMS nursing home staffing mandate.

Posters presented at SLEEP 2024 found reduced total sleep time among adolescents on weeknights, leading to less total sleep, as well as a link between lower sleep duration and poor mental health.

Young and educated men who have sex with men (MSM) were more likely to use self-testing for HIV.

A session at the SLEEP 2024 Annual Meeting discussed the various inequities in sleep that persist in individuals who are incarcerated, attend university, or work at hospitals.

Patients in dental settings had a comparable uptake of point-of-care HIV tests when compared with non-specialized health settings.

Phase 1 trial results indicate that combining inotuzumab ozogamicin with dose-adjusted EPOCH chemotherapy could offer a safe, well-tolerated, and effective treatment option for patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia or lymphoma (R/R B-ALL).

Posters presented at ASCO 2024 found positive responses in the prediction of tumor types and prognostic outcomes in patients with advanced solid tumors and HR+/HER2-negative (HER2–) metastatic breast cancer.

This investigation sprung from a lack of current knowledge on the impact of nonmalignant results following thoracic surgery for lung cancer, according to the authors.

US News releases ranking of the best 53 hospitals across 26 states serving socioeconomically disadvantaged communities with high-quality care.

Associations between ambient air pollutants and dry eye could have been mitigated during the pandemic.

The multinational, open-label, controlled, randomized, crossover, phase 3 TAK-755 (NCT03393975) trial demonstrated superior efficacy and safety of recombinant ADAMTS13 as prophylaxis in patients with congenital thrombotic thrombocytopenic purpura (cTTP) compared with standard therapy.

FDA advisers have voted against the use of MDMA as a post-traumatic stress disorder (PTSD) treatment; House members have expressed support for the 340B drug discount program but disagreed on whether it needs tighter regulation; a federal judge sided with SCAN Health Plan over CMS about incorrect 2024 Star Rating calculations.